BCLI Brainstorm Cell Therapeutics Inc.

4.02
-0.01  -0%
Previous Close 4.03
Open 4.03
Price To Book 8.38
Market Cap 83243093
Shares 20,707,237
Volume 27,006
Short Ratio
Av. Daily Volume 68,470

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data mid-2020. Interim safety analysis due by July 2019.
NurOwn
Amytrophic lateral sclerosis (ALS)
Phase 2 commencement of enrolment announced March 14, 2019.
NurOwn
Progressive Multiple Sclerosis

Latest News

  1. Atlas Blockchain Announces Definitive Agreement for the Acquisition of Isracann and Amendment to Investor Services Agreement
  2. BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS…
  3. BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
  4. Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
  5. The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
  6. BrainStorm to Host Business Update Conference Call
  7. BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
  8. BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
  9. BrainStorm Issues a Statement to Patients and Shareholders
  10. BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
  11. BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
  12. BrainStorm Granted Additional Patent for NurOwn® in Israel
  13. BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
  14. BCLI: Initiating Phase 2 Study in Progressive Multiple Sclerosis…
  15. BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
  16. BrainStorm Issues 2018 Letter to Shareholders
  17. BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial
  18. FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
  19. BrainStorm gets FDA okay for stem cell trial in MS patients
  20. BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND